CanWell Pharma’s First-in-Class innovative drug CAN2109 granted IND approval by China National Medical Products Administration (NMPA)
CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted IND approval by the China National Medical Products Administration (NMPA). CanWell plans to immediately initiate the patient enrollment…
CanWell’s CAN2109 IND Granted Approval by US FDA
CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted clinical approval by the US Food and Drug Administration (FDA) and it will soon conduct Phase I clinical…
Canwell to Present CAN1012 Research Update at the 4th STING & TLR Targeting Therapies Summit
CanWell announced today that the preclinical research results and clinical plan of the company’s TLR7 agonist CAN1012 would be presented at the 4th STING & TLR Targeted Therapy Summit in…
CanWell was Invited to Present at 9th Immuno-oncology 360° (IO360°) Conference
CanWell presented the preclinical research results of CAN1012, a small molecule TLR7 agonist in the form of an oral presentation at the 9th Immuno-oncology 360° (IO360°) conference. The IO360° conference…
CanWell presented the preclinical research results of CAN1012 at the annual meeting of the Society for Immunotherapy of Tumors (SITC)
CanWell announced today that the preclinical results of its small molecule TLR7 agonist CAN1012 were presented at the 37th Annual Meeting of the Society for Immunotherapy of Tumors (SITC 2022,…
First patient dosed in CanWell’s CAN1012 Ph1 Trial in China
CanWell Biotech Ltd. , a company specializing in the development of innovative immune-oncology drugs, announced today that the 1st patient has been successfully dosed in its ongoing CAN1012 Ph1 clinical…
CanWell’s TLR7 Agonist CAN1012 Received IND Approval by CDE in China
Canwell announced today that its TLR7 agonist CAN1012 had obtained clinical trial approval from China’s Center for Drug Evaluation (CDE). The approval allows CanWell to conduct Phase I clinical trials…
CanWell’s TLR7 Agonist CAN1012 IND Granted Approval by US FDA
CanWell Pharma announced that its First-in-Class innovative drug, TLR7 agonist CAN1012, has been granted clinical approval by the US Food and Drug Administration (FDA) and will soon conduct Phase I…
Professor Qiang Pan-Hammarström Named Member of Scientific Advisory Board at CanWell
CanWell announced today that Professor Qiang Pan-Hammarström has joined the Scientific Advisory Board (SAB) at CanWell. Professor Pan-Hammarström is a leading researcher in studying the genetic mechanisms and treatment of…
CanWell submits to US FDA the Investigational New Drug (IND) for its TLR7 agonist CAN1012 for Cancer Treatment
CanWell Pharma announced today that its independently developed First-in-Class innovative drug, TLR7 agonist, was submitted to the US Food and Drug Administration (FDA) for Investigational New Drug (IND) application and…